FacebookTwitterGoogle+RedditEmail

How Corrupt is Malcolm Gladwell?

by FRED GARDNER

Malcolm Gladwell is an influential New Yorker writer, the author of two best-sellers, “The Tipping Point” and “Blink.” In January the NYer published a Gladwell piece called “Open Secrets,” a convoluted defense of Enron’s management. Joe Nocera of the New York Times expressed surprise that the renowned Gladwell could write something so inaccurate and slanted.

“Already ‘Open Secrets’ has been embraced by those who argue that the Enron prosecutions were an effort to ‘criminalize’ what amounted to flawed business decisions,” wrote Nocera. “The efforts to weaken Sarbanes-Oxley are also rooted in the idea that the country overreacted to Enron and the other corporate scandals. In effect, the central defense argument -that Enron didn’t really do anything illegal- has been given new life by Mr. Gladwell. And it isn’t remotely true.”

It should come as no surprise that Malcolm Gladwell is a corporate shill. In 1997 the New Yorker published his paean to hormone replacement therapy, “The Estrogen Question: How Wrong is Dr. Susan Love?,” in which Gladwell derided Love’s warning that HRT could cause breast cancer. (Love, a distinguished clinician and UCLA professor, had been publicizing The Nurse’s Health Study finding that women taking Wyeth’s Prempro had a higher rate of breast cancer.) Gladwell’s piece culminated in a plug for Eli Lilly’s new drug Raloxifene, which was about to be marketed as Evista. “Before very long,” wrote Gladwell, “women worried about raising their breast-cancer risk will have the option of taking a different kind of hormone that doesn’t affect their breasts at all -or that may even protect against breast cancer.”

Raloxifene, Gladwell explained, represented “the next generation of HRT, the compounds known as serms (for ‘selective estrogen receptor modulators’).” To those tracking the marketing of Prozac it was obvious that Lilly, having made billions off its “selective serotonin reuptake inhibitor” anti-depressant, was reapplying the patter to its HRT drug. Gladwell scolded Love for not applauding the advent of serms. “You might think that it would be of enormous significance to Love, answering, as it does, her great worry about the potential side effects of HRT” Gladwell’s tone was coolly condescending throughout. “What Love has done is recalculate the risk-benefit equation for estrogen,” he asserted, “which is fine, except that she consistently overstates the risks and understates the benefits.”

Gladwell’s defense of HRT is a textbook example of corporate damage control. Step #1 when a study reveals the harmful effects of your product is to cite other studies drawing different conclusions. “I just reviewed the hormone/breast-cancer research from the last five years,” Gladwell quotes an epidemiologist named Trudy Bush; “I found four reports -two very large and well done- showing no effect, and I found another study showing that estrogen gave women significant protection against breast cancer. They’re all over the place.” Claiming that existing studies are inconclusive and that more research is needed sounds reasonable and usually gives the drug company 10 extra marketing years. In the case of Prempro, Wyeth only got five because the leaders of the Women’s Health Initiative had seen enough by 2002.

Step #2 is to attack the methodology of the revealing study. Gladwell faults the Nurses Health Study for “selection-bias problems The estrogen users, for example, had fewer pregnancies, got their periods earlier, and have other differences with the control group which would lead you believe that they might have had a higher risk of breast cancer anyway. There is another possible complication: estrogen does such a good job of fighting heart disease that most women who are on HRT live substantially longer than women who aren’t.” (That’s Step #3, the Bold Inversion. Gladwell’s sounds like it came from the same Lilly flack who reasoned that Prozac leads to suicide because it enables severely depressed people to overcome their lethargy.)

Step #4 is simply smearing the messenger. If a researcher’s professional credentials are unassailable, there’s always guilt by association. Just as Lilly (falsely) linked their foremost critic, Peter Breggin, MD, to the Scientologists, Gladwell puts Love in a vaguely disreputable “media-celebrity” category. “Her objection,” he writes, “is to the idea that postmenopausal women should rely on any sort of drug at all. This is where, sooner or later, you end up when you start down the path of people like Andrew Weil and Deepak Chopra and Susan Love.”

In a 2001 article by Gladwell extolling the anti-malarial effects of DDT, the woman who had gotten her science wrong was Rachel Carson. DDT, according to the man Gladwell touted as the great authority, “ought to be used as selectively as possible, to quell major outbreaks,” i.e., the present ban should be rescinded.

The massive, worldwide application of DDT had been promoted in the 1940s and ’50s by a Rockefeller Foundation functionary named Fred Soper who, according to Gladwell, “ranks as one of the unsung heroes of the twentieth century.” As it became clear that worldwide eradication was impractical ­DDT-resistant mosquito strains developed- Soper discounted all evidence of failure. Gladwell describes Soper losing his temper at one meeting in response to “talk that was impeding eradication -the doubting, the equivocation, the incompetence, the elevation of songbirds over human life”

In 2002, as data from the Women’s Health Initiative confirmed that women taking HRT are more likely to get breast cancer, blogger Mickey Kaus quoted some of Gladwell’s putdowns of Love and asked if he stood by his NYer piece. Gladwell emailed: “i was waiting for someone to write that! okay, here’s my answer: kausfiles is quite right. i was wrong, and susan love ought to feel vindicated. this is the perilous–and, of course, fun– part of writing about medicine. every now and again, scientists discover something new that turns everything we all thought we understood upside down.”

This is a bizarre response -as if what was at stake were Susan Love’s feelings, not the well-being of the women who started hormone replacement therapy or chose to stay on it thanks to his misleading New Yorker piece. Malcolm Gladwell, author of best-sellers, may know jack about science but he knows plenty about promoting ideas and products. If he regretted having advised women to take cancer-causing drugs, he should have seen to it that a retraction was widely disseminated instead of burying a comment on kausfiles, where it didn’t even warrant an item unto itself. And how about his “waiting” to be called out? Translation: “i was hoping no one would remember.”

Gladwell, a lightweight, is not entirely to blame for the damage his HRT article has done. The New Yorker should not have run it in 1997 and had an obligation in 2002 to notify readers that their reporting on “the estrogen question” had been wrong. The decision to take HRT drugs was and is a matter of health or cancer, life or death.

Gladwell’s musings about Enron were authorized by editor David Remnick and accompanied by a full-page colored cartoon by S. Chwast in which an executive seated at a desk is looking at a computer screen showing a graph trending downward while investigators in black suits and sunglasses examine files and wastebaskets, take notes and photos, and peer from behind potted palms -without looking at the screen. The caption reads, “Was the trouble with Enron that its management didn’t tell us enough -or that analysts failed to make sense of the data it supplied?” The NYer has stooped to shilling for Skilling.

FRED GARDNER edits O’Shaughnessy’s, the Journal of Cannabis in Clinical Practice (soon to have a presence on the web). He can be reached at fred@plebesite.com

 

Fred Gardner is the managing editor of O’Shaughnessy’s. He can be reached at fred@plebesite.com

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

Weekend Edition
May 26, 2017
Friday - Sunday
Charles R. Larson
Review: Mary V. Dearborn’s “Ernest Hemingway”
May 25, 2017
Jennifer Matsui
The Rise of the Alt-Center
Michael Hudson
Another Housing Bubble?
Robert Fisk
Trump Meets the New Leader of the Secular World, Pope Francis
John Laforge
Draft Treaty Banning Nuclear Weapons Unveiled
Benjamin Dangl
Trump’s Budget Expands War on the Backs of America’s Poor
Alice Donovan
US-Led Air Strikes Killed Record Number of Civilians in Syria
Andrew Moss
The Meaning of Trump’s Wall
Leslie Scott
Trump in the Middle East: New Ideas, Old Politics
George Wuerthner
Environmental Groups as Climate Deniers
Pauline Murphy
The Irish Dead: Fighting Fascism in Spain, 1937
Brian Trautman
Veterans on the March
Eric Sommer
Trumps Attack on Social Spending Escalates Long-term Massive Robbery of American Work
Binoy Kampmark
Twenty-Seven Hours: Donald Trump in Israel
Christian Hillegas
Trump’s Islamophobia: the Persistence of Orientalism in Western Rhetoric and Media
Michael J. Sainato
Russiagate: Clintonites Spread the Weiner Conspiracy
Walter Clemens
What the President Could Learn from Our Shih-Tzu Eddie
May 24, 2017
Paul Street
Beyond Neoliberal Identity Politics
Daniel Read
Powder Keg: Manchester Terror Attack Could Lead to Yet Another Resurgence in Nationalist Hate
Robert Fisk
When Peace is a Commodity: Trump in the Middle East
Kenneth Surin
The UK’s Epochal Election
Jeff Berg
Lessons From a Modern Greek Tragedy
Steve Cooper
A Concrete Agenda for Progressives
Michael McKinley
Australia-as-Concierge: the Need for a Change of Occupation
William Hawes
Where Are Your Minds? An Open Letter to Thomas de Maiziere and the CDU
Steve Early
“Corporate Free” Candidates Move Up
Fariborz Saremi
Presidential Elections in Iran and the Outcomes
Dan Bacher
The Dark Heart of California’s Water Politics
Alessandra Bajec
Never Ending Injustice for Pinar Selek
Rob Seimetz
Death By Demigod
Jesse Jackson
Venezuela Needs Helping Hand, Not a Hammer Blow 
Binoy Kampmark
Return to Realpolitik: Trump in Saudi Arabia
Vern Loomis
The NRA: the Dragon in Our Midst
May 23, 2017
John Wight
Manchester Attacks: What Price Hypocrisy?
Patrick Cockburn
A Gathering of Autocrats: Trump Puts US on Sunni Muslim Side of Bitter Sectarian War with Shias
Shamus Cooke
Can Trump Salvage His Presidency in Syria’s War?
Thomas S. Harrington
“Risk”: a Sad Comedown for Laura Poitras
Josh White
Towards the Corbyn Doctrine
Mike Whitney
Rosenstein and Mueller: the Regime Change Tag-Team
Jan Oberg
Trump in Riyadh: an Arab NATO Against Syria and Iran
Susan Babbitt
The Most Dangerous Spy You’ve Never Heard Of: Ana Belén Montes
Rannie Amiri
Al-Awamiya: City of Resistance
Dimitris Konstantakopoulos
The European Left and the Greek Tragedy
Laura Leigh
This Land is Your Land, Except If You’re a Wild Horse Advocate
Hervé Kempf
Macron, Old World President
FacebookTwitterGoogle+RedditEmail